Dedicated to driving collaborations among individuals and organizations worldwide committed to discovering, developing, and delivering the latest and most promising treatments for all types of sarcomas.

  • Friday
  • Jun 3
  • 2022

SARC032 Expanded

SU2C has made additional funds available for SARC032 so that we can increase the sample size and power of this randomized, ongoing trial from 102 to 126 evaluable patients. We appreciate the SARC community for already accruing 96 evaluable patients and we encourage additional enrollment so that we can complete this important study.

Read more

Meet the people of SARC

Angel Parry, MPA

Angel Funk Parry joined SARC in February 2022 as Development Associate. Angel earned her Master of Public Administration, Specializing in Nonprofit Management at the University of North Carolina Wilmington.